These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. Ji J; Watts GF; Johnson AG; Chan DC; Ooi EM; Rye KA; Serone AP; Barrett PH J Clin Endocrinol Metab; 2006 Mar; 91(3):973-9. PubMed ID: 16368749 [TBL] [Abstract][Full Text] [Related]
23. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Millar JS; Duffy D; Gadi R; Bloedon LT; Dunbar RL; Wolfe ML; Movva R; Shah A; Fuki IV; McCoy M; Harris CJ; Wang MD; Howey DC; Rader DJ Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):140-6. PubMed ID: 18988892 [TBL] [Abstract][Full Text] [Related]
24. Effect of weight loss on LDL and HDL kinetics in the metabolic syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Ng TW; Watts GF; Barrett PH; Rye KA; Chan DC Diabetes Care; 2007 Nov; 30(11):2945-50. PubMed ID: 17686833 [TBL] [Abstract][Full Text] [Related]
25. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Ooi EM; Watts GF; Chan DC; Pang J; Tenneti VS; Hamilton SJ; McCormick SP; Marcovina SM; Barrett PH Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2686-93. PubMed ID: 26515419 [TBL] [Abstract][Full Text] [Related]
26. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion. VerHague MA; Cheng D; Weinberg RB; Shelness GS Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551 [TBL] [Abstract][Full Text] [Related]
27. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Ooi EM; Barrett PH; Watts GF Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Avramoglu RK; Qiu W; Adeli K Front Biosci; 2003 Jan; 8():d464-76. PubMed ID: 12456312 [TBL] [Abstract][Full Text] [Related]
30. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. Riches FM; Watts GF; Hua J; Stewart GR; Naoumova RP; Barrett PH J Clin Endocrinol Metab; 1999 Aug; 84(8):2854-61. PubMed ID: 10443691 [TBL] [Abstract][Full Text] [Related]
31. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160 [TBL] [Abstract][Full Text] [Related]
32. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Olson EJ; Pearce GL; Jones NP; Sprecher DL Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748 [TBL] [Abstract][Full Text] [Related]
33. Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome. Ooi EM; Barrett PH; Chan DC; Nestel PJ; Watts GF Atherosclerosis; 2008 Mar; 197(1):139-46. PubMed ID: 17416370 [TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204 [TBL] [Abstract][Full Text] [Related]
35. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans. Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454 [TBL] [Abstract][Full Text] [Related]
36. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux. Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238 [TBL] [Abstract][Full Text] [Related]
37. Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study. Vergès B; Adiels M; Boren J; Barrett PH; Watts GF; Chan D; Duvillard L; Söderlund S; Matikainen N; Kahri J; Robin I; Taskinen MR J Clin Endocrinol Metab; 2014 Nov; 99(11):4281-90. PubMed ID: 25077901 [TBL] [Abstract][Full Text] [Related]
38. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160 [TBL] [Abstract][Full Text] [Related]